TABLE 2

PKs as markers of diseases

Prokineticin 1 (PK1)
DiseaseReference
Colorectal cancer(Tagai et al., 2021)
Gastrointestinal tumor(Goi et al., 2013)
Human gliomas(Xiao et al., 2017)
Implantation failure(Karaer et al., 2020)
Lower-grade glioma(Zhong et al., 2022)
Obstetric disorders(Su et al., 2017)
Preeclampsia(Wang et al., 2019)
Temporomandibular joint disorders(Herr et al., 2011)
Prokineticin 2 (PK2)
DiseaseReference
Alzheimer(Lattanzi et al., 2019b)
Arthritis(Noda et al., 2021)
Cervical cancer(Wu et al., 2020)
CNS autoimmune demyelinating disease(Abou-Hamdan et al., 2015)
Colorectal cancer(Yoshida et al., 2018)
Diabetes(Mortreux et al., 2019)
End stage cardiac failure(Urayama et al., 2007)
Hepatocellular carcinoma(Monnier et al., 2008)
Huntington's disease(Mastrokolias et al., 2015)
Inflammation-induced pain(Jacobson et al., 2011)
Klinefelter's syndrome(Fiore et al., 2022)
Lower-grade glioma(Zhong et al., 2022)
Lung metastasis(Kowanetz et al., 2010)
Metabolic syndrome(Wang et al., 2016)
Neuroendocrine neoplasms(Puliani et al., 2022)
Obesity(Wang et al., 2021)
Osteoporosis(Zhang et al., 2022b)
Parkinson(Schirinzi et al., 2021, 2022)
Pneumonia(Tu et al., 2022)
Post-COVID olfactory recovery(Schirinzi et al., 2023)
Pregnancy pathology(Alfaidy et al., 2014)
Prostate cancer(Zhong et al., 2009)
Septic choc Sepsis (Yu et al., 2022)
Skin cancer(Lauttia et al., 2014)